Toronto, Ontario (March 26, 2021) – Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF)  (FRA: 1OA) the Canadian parent of Blueberries S.A.S., the premier Latin American licensed  cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together  the “Company” or "Blueberries"), today announced that it has signed a Framework Agreement  with Mechelen S.A., a subsidiary of YVY Life Sciences (“YVY”) for mutual development of strains  and genetics in Colombia and potentially exporting dry cannabis flower of mutual strains from  Uruguay. 

This is Blueberries’ first agreement in Uruguay and the next step in Blueberries’ international  growth strategy under way. In December 2013, Uruguay, became the first country in the world to  legalize recreational cannabis, starting a ripple effect throughout the world and particularly in Latin  America, which continues to this day. With this agreement, Blueberries will expand its reach to a  new jurisdiction, and through the Mercosur Regional Free Trade Bloc, will gain access to Brazil. 

Latin America, which includes Colombia, Argentina, Peru and Uruguay, is a highly populous  potential market, with countries that have recent or pending legislation permitting access to  cannabis and CBD oils for medicinal use. 

YVY is dedicated to the production of dried flowers of medicinal cannabis with their focus on  sustainable and high-quality cannabis and hemp cultivation, harvesting their first sustainable  crops in April 2020. 

“We are incredibly pleased with the concept of co-developing new cannabis genetics in  collaboration with YVY, and with the opportunity to replicate their unique cultivation model that  will bring multiple benefits to our operations in Colombia.” said Jose Forero, Blueberries President of Latin American Operations, “Likewise, we are excited with the opportunity to register our top  genetics in other countries. Uruguay is the perfect jurisdiction to start our expansion into new  geographies and potentially export dry flower, something that is not yet allowed in Colombia.” 

The Framework Agreement, dated March 24, 2021, has an initial term of five years, with  customary renewal clauses and no consideration paid by neither party. It is intended as the first  step in the relationship with specific accessory agreements to follow in the coming months. Under  the Framework Agreement, Blueberries and YVY will structure collaborative plans, initially starting  with mutual development of strains and genetics in Colombia, and consequently registration of  those cultivars both in Colombia and Uruguay. This will provide a fast-track opportunity to register  Blueberries’ proprietary genetics in Uruguay, thus allowing the partners to cultivate and export  dry flower of Blueberries’ strains from Uruguay.  

“We are thrilled with this strategic alliance with Blueberries as we venture beyond Uruguay. Our  goal is to work closely with Blueberries to replicate YVY’s unique cultivation model with small  producers in Colombia, producing high-quality and natural products while generating scalable  social and environmental impact,” said Andrea Krell, Chief Executive Officer of YVY. “Our vision  is to use the Framework Agreement as the first step in a long-term strategic partnership which 

will help us quickly take practical steps in developing collaborative projects both in Colombia and  Uruguay.” 

About YVY Life Sciences 

YVY is a cannabis lifestyle brand comprising of natural and high-quality products, powered by an  innovative and unique cultivation model. YVY operations are currently in Uruguay with expansion  plans underway in Colombia and Argentina with potential distribution in Latin America and  Europe. YVY’s focus and expertise is the cultivation of high-quality cannabis flower, biomass and  seeds incorporating genetics R&D and strict quality control. YVY works with strategic partners to  manufacture, formulate, and distribute YVY branded products targeting the wellness segment.  

For more information about the YVY visit www.yvylifesciences.com, or please contact: 

Andrea K Krell, Chief Executive Officer 

andrea@yvylifesciences.com 

Tel: +598 92 151 456 

About Blueberries Medical Corp. 

Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis  with its primary operations ideally located in the Bogotá Savannah of central Colombia. The  Company is led by a specialized team with proprietary expertise in agriculture, genetics,  extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation,  production, domestic distribution, and international export of CBD and THC-based medical  cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural  advantages and distribution arrangements has positioned the Company to become a leading  international supplier of naturally grown, processed, and standardized medicinal-grade cannabis  oil extracts and related products. 

Additional information about the Company is available at www.blueberriesmed.com. For more  information, please contact: 

Jose Forero, President, Latin American Operations 

jforero@blueberriesmed.com 

Tel: +57 310 345 8808 

Ian Atacan, Chief Financial Officer 

iatacan@blueberriesmed.com 

Tel: +1 (416) 562 3220 

Cautionary Note Regarding Forward-Looking Information 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements")  within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that  involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or  performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not  anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or  stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not  statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among  other things, to: commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP  standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is  contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in  Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international  markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation,  production, industrialization and marketing of cannabis for commercial and scientific purposes. 

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time  such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown  risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially

differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors,  among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations  regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the  Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain  adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation,  production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee  relations. Although the forward-looking statements contained in this news release are based upon what management of the Company  believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be  consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated  or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news  release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other  factors, should they change, except as required by law.  

Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained  under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at  www.sedar.com. 

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.